In a second cohort of 51 HER2+ BC cases26, ESTIMATE analysis indicated that non-relapsing patients after adjuvant HER2-targeted treatment were also characterized by increased immune/stroma ratio (Fig. 1b, right panel). Here, ERBB2 is linked to breast cancer.